haha777 new
Oxford Instruments ( OTCMKTS:OXINF – Get Free Report ) and Everspin Technologies ( NASDAQ:MRAM – Get Free Report ) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Volatility & Risk Oxford Instruments has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Everspin Technologies has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Valuation and Earnings This table compares Oxford Instruments and Everspin Technologies”s revenue, earnings per share (EPS) and valuation. Institutional & Insider Ownership 44.7% of Everspin Technologies shares are owned by institutional investors. 6.1% of Everspin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Analyst Ratings This is a breakdown of current recommendations and price targets for Oxford Instruments and Everspin Technologies, as reported by MarketBeat. Everspin Technologies has a consensus target price of $9.00, indicating a potential upside of 41.51%. Given Everspin Technologies’ higher possible upside, analysts clearly believe Everspin Technologies is more favorable than Oxford Instruments. Profitability This table compares Oxford Instruments and Everspin Technologies’ net margins, return on equity and return on assets. Summary Everspin Technologies beats Oxford Instruments on 8 of the 13 factors compared between the two stocks. About Oxford Instruments ( Get Free Report ) Oxford Instruments plc provide scientific technology products and services for academic and commercial organizations worldwide. It operates through three segments: Materials & Characterisation, Research & Discovery, and Service & Healthcare. The company offers atomic force, electron, and Raman microscopy; deposition tools comprising plasma enhanced chemical vapour deposition, chemical vapour deposition, inductively coupled plasma chemical vapour deposition, atomic layer deposition, and ion beam deposition systems; and etch tools, including inductively coupled plasma etching, reactive ion etching, deep silicon etching, atomic layer etching, and ion beam etching systems. It also provides low temperature systems, such as dilution refrigerators, high field magnets, and cryostats; optical imaging products, including cameras, confocal microscopy, and 3d and 4d visualisation software; nuclear magnetic resonance (NMR) products comprising NMR spectrometers, TD-NMR research, QA/QC analyzers, and rock core analyzers; and X-Ray sources, tubes, and power supply products. Its products are used in various industries, such as advanced manufacturing, agriculture and food, astronomy, automotive and aerospace, bio imaging and life science, chemical and catalysis, energy generation and storage, forensics and environment, geology, petrology, mining, metals, alloys, composites, ceramics, pharma, photonics, polymers, quantum technologies, semiconductors, microelectronics, and data storage. Oxford Instruments plc was founded in 1959 and is headquartered in Abingdon, the United Kingdom. About Everspin Technologies ( Get Free Report ) Everspin Technologies, Inc. engages in the manufacture and sale of magnetoresistive random access memory (MRAM) products in the United States, Japan, Hong Kong, Germany, Singapore, China, Canada, and internationally. It offers Toggle MRAM, spin-transfer torque MRAM, and tunnel magneto resistance sensor products, as well as foundry services for MRAM products. The company provides its products for applications, including industrial, medical, automotive/transportation, aerospace, and data center markets. It serves original equipment manufacturers, contract manufacturers, and original design manufacturers through a direct sales channel, and a network of representatives and distributors. Everspin Technologies, Inc. was incorporated in 2008 and is headquartered in Chandler, Arizona. Receive News & Ratings for Oxford Instruments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Instruments and related companies with MarketBeat.com's FREE daily email newsletter .
Judge rejects request to sideline a San Jose State volleyball player on grounds she’s transgender
NIIGATA: The Indian-born head of one of Japan’s most famous snack brands has warned that the country must change its mindset and admit more immigrants to get the economy back to the glory of its boom years. Politicians have struggled for years to recover from the so-called lost decades as a range of differing programs have failed to kickstart growth, including an ultra-loose monetary policy and trillions of dollars in stimulus measures. And as the new government of Prime Minister Shigeru Ishiba eyes a fresh drive to bring back the heyday of its global tech domination, Lekh Juneja, the head of rice cracker giant Kameda Seika, said he worries his adopted country has lost its edge. “Forty years ago I came to Japan because it was close to number one in GDP... it was booming,” the biotech scientist told AFP at Kameda’s headquarters in Japan’s rice heartland of Niigata. But at some point “Japan thought ‘we have everything now’. And I think that the hungry spirit to (have) the guts to go global started disappearing a bit”. Kameda’s expansion mirrored Japan’s postwar boom, increasing revenues tenfold between 1965 and 1974 and becoming synonymous with the nationally adored “senbei” crackers in the process. But the country that gave the world the Sony Walkman, the bullet train and Super Mario is no longer setting the pace in technology, overtaken by Silicon Valley, South Korea and China. In the late 1980s, Japanese firms dominated the world’s top 10 companies by market capitalization. Today not one makes the list. The population is ageing and projected to drop by almost a third in the next 50 years, and firms are already having problems filling vacancies. Although it has relaxed the rules in recent years, Japan has not turned in a big way to immigration as a solution. The country “has no choice” but to allow in more immigrants, said Juneja, 72, who first came to Japan in 1984 and previously worked for a food ingredients maker and a pharmaceuticals firm. “It’s not only the numbers. It’s also the mindset, the culture. We have to go global,” he said. According to a recent study, Japan needs to more than triple its number of foreign workers to 6.88 million by 2040. Currently it’s on track to be almost a million short. ‘Rice innovation’ Since joining the firm Juneja has been trying to make Kameda more international as well as a “rice innovation company”. In the testing center for new products the employees rolling out dough and trying out new recipes and flavors include an American and a Vietnamese. Language “is a big barrier. You bring people to Niigata and they don’t speak Japanese and it’s very difficult for them”, Juneja said. “We need to change that. (If we employ people) who only speak and write Japanese we have very limited resources, very limited choices,” he warned. Japan has very few foreign-born CEOs, and boardrooms are overwhelmingly male. There are 13 female CEOs in Japan’s 1,600 top-listed firms, a Kyodo News survey showed in September. “It’s very rare (for a foreigner) to become a CEO in a Japanese company,” Juneja said. “But look at the US.” “There is Microsoft, there is Google, all these companies have Indian CEOs,” he said. “I think Japan has to change... We are proud (in Japan) of our backgrounds. But I think flexibility and having people from overseas would be very critical for Japan.” Not all the non-Japanese CEOs have had a smooth ride. In November the German chief of Olympus resigned after allegedly buying illegal drugs. And in 2018 Carlos Ghosn, the Franco-Lebanese-Brazilian chief of Nissan, was arrested on suspicion of financial misconduct. He then escaped, in part by hiding in an audio equipment box. “He didn’t generate a very good image for foreign CEOs here,” Juneja said. “But the difference between him and me is that I have got a Japanese passport.” — AFPAP Business SummaryBrief at 5:52 p.m. EST
Agomelatine is a small molecule commercialized by Alto Neuroscience, with a leading Phase II program in Major Depressive Disorder. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for Agomelatine is expected to reach an annual total of $104 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Agomelatine Overview Agomelatine (ALTO-300) is under development for the treatment of major depressive disorder (MDD). It is administered through oral route. It acts by targeting MT1, MT2 and 5-HT2C. It was also under development for post-traumatic stress disorder (PTSD). Alto Neuroscience Overview Alto Neuroscience is a biopharmaceutical company that develops drugs for psychiatric and mental health conditions. It is investigating ALTO-100, ALTO-202, and ALTO-300 drugs for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) by targeting cognition, emotion, and sleep systems. The company utilizes its AI-enabled drug development platform that identifies biomarkers by evaluating brain function measures to develop its product candidates. It serves throughout the US. Alto Neuroscience is headquartered in Los Altos, California, the US. The operating loss of the company was US$37.8 million in FY2023, compared to an operating loss of US$29.2 million in FY2022. The net loss of the company was US$36.3 million in FY2023, compared to a net loss of US$27.7 million in FY2022. For a complete picture of Agomelatine’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .
Monster Beverage Co. (NASDAQ:MNST) Shares Sold by Pathstone Holdings LLC
Station Science Top News: Dec. 20, 2024United Airlines Unlocks Greater Travel Flexibility with New Third Daily Flight from San Francisco to Singapore in 2025: What You Need To Know
Kay Patterson, who rose from janitor at segregated South Carolina capitol to state senator, dies
TOKYO , Dec. 15, 2024 /PRNewswire/ -- Representatives from China and Japan shared their insights on promoting artificial intelligence (AI) governance and data sharing at a sub-forum of the 20th Beijing-Tokyo Forum in Tokyo recently. The sub-forum contributed eastern wisdom to AI governance and digital social development, demonstrating the significance of international cooperation for the development of the digital economy, according to Gao Shaolin, advisor at Peking University's Legal Artificial Intelligence Research Center. AI governance framework The participants agreed that the next 10 years will be a critical period for the development of AI. Gao Wen, academician of the Chinese Academy of Engineering (CAE), said since China's State Council issued a guideline on developing AI in 2017, the nation has made significant progress in AI research and development and industrial layout, especially in computing power and 5G network construction. By the end of 2023, China had over half of the world's 1.57 billion 5G users, according to the World Internet Development Report 2024. It ranked second globally in AI and computing power scale, which has laid a solid foundation for the rapid development of AI. Tatsuo Yamazaki , project professor at the International University of Health and Welfare, said it was very meaningful for Japan and China to discuss strengthening AI governance rules. Fumihiko Kamio , research director of the Nomura Research Institute, echoed his view. He emphasized that the core goal of AI technology is to improve productivity and eliminate obstacles to social development, and called on Chinese and Japanese experts to work together to build an AI governance framework to cope with the global challenges. Deepening international cooperation China put forth the Global AI Governance Initiative in October last year. In July, the UN General Assembly adopted a China -sponsored resolution on enhancing international cooperation on AI capacity-building. The participants spoke highly of the Global Cross-Border Data Flow Cooperation Initiative recently proposed by China . They agreed that AI governance requires global collaboration, especially in the formulation of international standards and the construction of ethical frameworks, where China and Japan can play an active role. Ding Wenhua, academician of the CAE, said China and Japan have both similarities and differences in technology development and governance priorities, so deepening cooperation will bring unique value to global AI governance. " China and Japan should deepen AI technology cooperation between enterprises, work together in AI security research, talent exchange, and jointly explore more possibilities for the application of technology," Wang Zhongyuan , president of the Beijing Academy of Artificial Intelligence, said. Balancing development & risks AI governance refers to the guardrails established to ensure AI systems and tools remain safe and ethical and respect human rights. Xu Zhilong , editor-in-chief of Science and Technology Daily, stressed that AI, as a revolutionary technology, has far-reaching impacts on all areas of society and economy. However, its potential risks such as data leakage and the spread of false information should not be ignored. "Technological progress and security ethics should be developed in a balanced way to ensure that AI technology always serves the progress of human civilization," Xu said. AI governance should not only heed the current technological ethics issues, but also prevent possible long-term risks, such as AI going out of human control, according to Toshio Iwamoto , senior corporate advisor of NTT DATA. He said AI R&D and application should abide by the principles of fairness, transparency, safety and availability. Yuan Yue, chairman of Beijing Dataway Horizon, shared his view from the perspective of regulatory models. "Policy choices should be based on the current status and goals of national technological development," Yuan said, adding that China prefers to provide a more friendly development environment for enterprises while ensuring an effective response to risks. View original content to download multimedia: https://www.prnewswire.com/news-releases/science-and-technology-daily-promoting-ai-governance-jointly-302332050.html SOURCE Science and Technology Daily
Fraser Health has launched a public awareness campaign encouraging pregnant people and people with syphilis symptoms to get tested for the sexually transmitted infection as cases continue to climb in British Columbia. In 2019 the provincial health officer declared a syphilis outbreak in B.C. based on rising case numbers. Since then the entire province has seen a “dramatic” increase in cases, said Dr. Vincent Valdrez, a BC Centre for Disease Control sexually transmitted infection physician. During the first six months of this year, B.C. had 1,049 cases of infectious syphilis, up from 154 cases in all of 2010. There were 1,060 cases in 2019, and 1,964 in 2022, according to the 2023 BC Syphilis Action Plan Refresh. A decade ago most syphilis cases were among men who have sex with men, but today two-thirds of syphilis cases occur in people who report having only heterosexual partners, and one-third of all cases are in women, he said. To boost public awareness about syphilis and the importance of testing, Fraser Health has placed ads on buses and bus stops. They’ve also placed digital ads in Fraser Health facilities, online and on Facebook and Instagram, the health authority told The Tyee in an email. Valdrez said it’s not clear why case counts are increasing and the demographics are significantly shifting, but it’s important that people know that anyone who is sexually active has some risk of contracting an STI. Testing is recommended for anyone who has never been tested, has a sexual partner who tested positive, is pregnant or has a new sexual partner, and, of course, anyone who is symptomatic. Regular testing at least every few months is recommended for anyone who has multiple sexual partners or engages in other activities that can increase the risk of exposure, such as sex work. Syphilis is a bacterial infection that is usually transmitted through sexual contact, often through a lesion like a genital ulcer, but also can be transmitted when the infected person is asymptomatic, Valdrez said. A pregnant person can also transmit the infection to their developing fetus. The first stage usually consists of a painless sore or sores on the genitals, lips, mouth or anus. The infection then spreads to the rest of the body. At the second stage, symptoms can include a non-itchy rash on the chest, belly, genitals, palms or soles of the feet, having a headache, fever, hair loss or swollen lymph nodes, and having bumps or patches inside the mouth, anus and genitals, according to the SmartSexResource, a service provided by the BC Centre for Disease Control. Syphilis is called the “great mimicker” because these symptoms are non-specific and can be mistaken for other conditions, Valdrez said. It’s important for individuals but also clinicians to be aware of the symptoms and to include syphilis testing when trying to diagnose an illness. The third stage is called the “dormant” or “latent” phase, Valdrez said. It doesn’t have symptoms but can still be contagious. Within as little as a year after infection, syphilis can spread to different organ systems, such as the nervous system, he said. An infection can make people “go blind, [or] people can lose their hearing and it can spread to the brain and people can get strokes or seizures,” which are caused by inflammation around the brain, Valdrez said. “It’s very important to catch syphilis early and to treat it early to prevent these longer-term effects,” Valdrez said. Congenital syphilis An increase in infections in people assigned female at birth is doubly concerning because of the risk of congenital syphilis, in which a pregnant person can transmit the infection to a developing fetus, Valdrez said. Congenital syphilis can mean “babies are quite sick when they’re born, and it can lead to long-term health effects, in their immediate future but also later in life,” he added. Congenital syphilis can result in premature birth, low birthweight and other serious debilitating conditions, including stillbirth, according to Fraser Health. In 2022, over 90 per cent of women with infectious syphilis were between the ages of 15 and 49, according to the 2023 BC Syphilis Action Plan Refresh. There were 355 cases of infectious syphilis in females aged 15 to 49 during the first half of this year, according to the BC Centre for Disease Control. Twenty-three of those cases were diagnosed during prenatal screening. There were 21 cases of congenital syphilis in 2023, up from two cases in 2020, Fraser Health said. In 2019 B.C. introduced a new guideline for pregnant people to test for syphilis during the first trimester or at the first prenatal visit, and again during delivery. Valdrez said a syphilis blood test ideally happens during the first trimester so there are at least four weeks between when they get treatment and when they deliver. This “would ensure a treatment of the syphilis infection in both the pregnant person and the prevention of transmission to the baby,” he said. Unfortunately people aren’t always interacting with the health-care system during their first trimester of pregnancy, he said. There are complex reasons why people don’t access medical care at regular intervals, he added. For example, a person may be unhoused and learn they are pregnant and have syphilis only when they seek emergency care for an unrelated issue, he said. Late is better than never, he said. The good news: syphilis is curable The good news is that testing and treatment for STIs is free in B.C., and that syphilis can be cured with antibiotics at any stage of the infection. Further good news is that, so far, there haven’t been any antibiotic-resistant cases of syphilis found in the province, Valdrez said. British Columbians can speak with their doctor about getting tested for STIs, or use other free and confidential testing services like the BC Centre for Disease Control’s GetCheckedOnline. GetCheckedOnline allows people to make a lab form that they can take to participating labs for free STI testing. Participants don’t need to provide their name or have a Medical Services Plan number — you just need to provide an email and phone number. There are participating labs in Vancouver, Maple Ridge, Victoria, Duncan, Kamloops, Kimberley and Nelson. Vancouver is also home to the BC Centre for Disease Control’s STI clinic, located near City Hall and open six days a week. The STI clinic offers free and confidential testing and treatment, and patients are not required to be enrolled in B.C.’s provincial health care. Options for Sexual Health has 60 clinics across the province that provide free STI testing and treatment for people enrolled in MSP. Those without MSP coverage may be charged up to $200, depending on the service, and Options for Sexual Health does not offer anonymous testing like GetCheckedOnline or the BC Centre for Disease Control STI clinic. Syphilis can be treated for free in B.C. with penicillin injections. Urgent and primary care centres, emergency departments, sexual health clinics, community health centres and public health centres will generally have these stocked, or a doctor could order and administer the treatment regardless of where you live in B.C., Valdrez said. Alternative antibiotics are available for people with penicillin allergies; people should discuss options with the doctor who is treating them. Men who have sex with men and are at high risk of contracting STIs should speak with their doctor about other preventive measures they could take, Valdrez added.Trump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’Dominos secret all-you-can-eat pizza deal is real, but it isn’t advertised anywhere
Nvidia’s Future Looks Brighter with Blackwell GPUs Morgan Stanley continues to regard Nvidia as a standout in the technology sector, maintaining its “Top Pick” status with an “Overweight” rating and a $166 price target. The firm is focusing on the immense demand for Nvidia’s upcoming Blackwell GPU as a primary growth driver, setting aside any temporary setbacks the company might face. Under the guidance of Joseph Moore, Morgan Stanley’s insights suggest that Nvidia’s current issues are fleeting and have a negligible impact on its long-term success. Moore anticipates that once the Blackwell GPUs gain market momentum by late 2025, they will dominate industry discussions due to their significant potential to boost Nvidia’s revenues. This aligns with data from Trendforce, which forecasts booming sales for Nvidia during the second and third quarters, coinciding with expectations for increased Blackwell GPU production in early 2025. Morgan Stanley projects Nvidia’s revenue to surge by 44.1% in 2025, outpacing competitors such as Broadcom and AMD. Adding to the excitement, Nvidia is set to make a notable appearance at the Consumer Electronics Show in January, where CEO Jensen Huang will deliver a keynote address. Analysts anticipate Nvidia will utilize this platform to showcase the expected high demand for Blackwell GPUs, further asserting its market dominance. Morgan Stanley remains optimistic about easing supply constraints by mid-2025, positioning Nvidia to fully capitalize on the Blackwell launch and further consolidate its leadership in the GPU arena. Unveiling Nvidia’s Blackwell GPUs: A Game-Changer on the Horizon In the competitive landscape of advanced computing technology, Nvidia continues to assert its dominance with the upcoming release of the Blackwell GPUs. Industry analysts are predicting that these GPUs will drive significant growth and innovation within the sector. Specifications and Innovations of Blackwell GPUs While specific details of the Blackwell architecture remain under wraps, experts suggest that these GPUs will feature cutting-edge advancements in processing power, energy efficiency, and AI acceleration capabilities. The anticipated improvements are expected to set new industry benchmarks, appealing especially to sectors that demand high-performance computing, including gaming, artificial intelligence, and data centers. Predictions: Market Impact and Growth Morgan Stanley and Trendforce project strong market demand for the Blackwell GPUs, pinpointing late 2025 as the period when these products will hit critical market momentum. With projections of Nvidia’s revenue increasing by an impressive 44.1% in 2025, Blackwell GPUs are poised to significantly outpace competitors like Broadcom and AMD. Use Cases and Compatibility The Blackwell GPUs are anticipated to have broad compatibility with various systems, enhancing their appeal across multiple industries. Their use cases are expected to expand into fields such as virtual reality, machine learning, and autonomous vehicles, where high computational power is crucial. How Nvidia Plans to Maintain Leadership Nvidia’s strategy to maintain its leadership involves aggressively addressing supply chain constraints and leveraging key industry events, like the upcoming Consumer Electronics Show (CES) in January, where CEO Jensen Huang is slated to showcase the anticipated demand and innovations of the Blackwell GPUs. This event is crucial for highlighting Nvidia’s forward-thinking approach and technological prowess. Enhancing Sustainability in Tech A noteworthy aspect of Nvidia’s new line is its focus on sustainability. Industry insiders anticipate that the Blackwell GPUs will incorporate energy-efficient designs, contributing to reducing the overall carbon footprint of high-performance computing solutions. Market Analysis As the demand for more powerful and efficient GPUs grows, Nvidia is strategically positioned to capitalize on this trend with their Blackwell release. The company’s strong market presence and strategic foresight appear well-aligned to lead the industry in this new era of GPU technology. For more information on Nvidia and its innovations, visit the official Nvidia website . By focusing on these upcoming innovations and strategies, Nvidia aims to solidify its leader status in the technology market and meet the evolving needs of its consumers.Ukraine collects vast war data trove to train AI modelsTrump picks Pam Bondi for next attorney general
The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.Sebastian Coe says new Ultimate Championship will be athletics ‘gamechanger’